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Abstract
To evaluate the ocular safety of intravitreal carboplatin and digoxin injections as a new
intravitreal chemotherapy option for retinoblastoma tumor vitreous seeds. Eighteen rabbits were divided randomly into three groups to receive intravitreal injection of Digoxin
(6 rabbits), Carboplatin (7 rabbits), or Saline (5 rabbits). In every group, one eye randomly
treated with 10 µg Digoxin in 0.1 cc or 1 µg Carboplatin or Saline, and the contralateral
eye was considered as the control. All groups underwent three consecutive injections of
the drugs with 1-week intervals. Baseline electroretinography (ERG) was recorded from
both eyes of all the animals prior to injection and was repeated 1st day, 1st week, and
1st month after the last injection. All rabbits were sacrificed 1 month after the last injection, and histological studies were done. Mean a and b wave amplitudes decreased significantly at 1st day, 1st week, and 1st month after the last intravitreal injection of 10 µg
Digoxin in comparison with other groups (p-value: .02). Contradictory, 1 µg Carboplatin
injected eyes had minimal ERG changes. There were some nonspecific ERG changes with
unclear clinical significance in non-injected contralateral control eyes of Digoxin and
Carboplatin groups in comparison with the control eyes of the Saline group. Histological
studies revealed considerable neural retinal atrophy in injected eyes of the Digoxin group.
Intravitreal 10 µg Digoxin might have more local ocular toxicity in comparison with intravitreal Carboplatin in albino rabbit eyes. Future studies should assess the induced toxicity
of intravitreal injection of these drugs on the non-injected contralateral eye.
KEYWORDS
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I NTRO D U C TI O N

the management of retinoblastoma2 it is often tough to achieve complete tumor control in the presence of the vitreous seeds.3,4

Retinoblastoma is the most prevalent childhood primary intraocular

The rate of eye salvage varies based on the International

1

malignant tumor with incidence of 1 per 15,000–20,000 live births.

Intraocular Retinoblastoma Classification (IIRC).5 It can be as high

Although systemic chemotherapy has become the cornerstone in

as 100% for group A eyes, 96% for group B eyes, 90% for group C

Abbreviations: ERG, electroretinography; IIRC, International Intraocular Retinoblastoma Classification; RPE, retinal pigment epithelium.
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eyes, and 48% for group D eyes.6 The lower eye salvage rate for

response and no therapeutic response with systemic Digoxin.38 Only

group D eyes (defined by the presence of diffuse vitreous seeds) is

one study in the literature assessed the safety of a single intravitreal

usually due to active vitreous seeds.3,4 Intra-arterial chemotherapy

Digoxin injection in preclinical retinoblastoma models. 29

increased group D's eye salvage levels to 70%. (64 percent for vitreous seeds and 83 percent for subretinal seeds).7–9

In this experimental study, we intended to compare the ocular safety of repeated intravitreal injections of 1 µg Carboplatin

Vitreous seeds are hard to manage with chemotherapy because

and 10 µg Digoxin in healthy albino rabbits based on the previous

the vitreous is avascular and chemotherapy cannot reach the opti-

studies. 29,31 We aimed to assess the possible toxicity of these drugs

10

mum therapeutic levels.

Moreover, due to blood ocular barriers,

on the retina based on the electroretinography (ERG) findings as a

systemic administrated chemotherapeutic drugs do not diffuse in to

functional test, as well as structural evaluations on histopathological

11

the vitreous cavity adequately.

on the other hand, systemic che-

specimens from enucleated eyes.

motherapy can also be associated with serious systemic risks such
as myelosuppression, nephrotoxicity, ototoxicity, sepsis, second tumors, and death, preventing higher doses of medicines.12

2
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M ATE R I A L S A N D M E TH O DS

External beam radiotherapy has been reported as a reliable
method to treat vitreous seeds with a salvage rate of 91%13; how-

This investigation was conducted in the animal laboratory of Farabi

ever, it was associated with remarkable side effects such as second-

eye hospital, Tehran, Iran, between August and October 2018. This

ary malignancies besides having other ocular side effects.14 Various

study was approved by the ethical committee of the Farabi Eye

15

16

and periocu-

Research Center and Tehran University of medical science. All the

lar17 chemotherapy have been developed to improve the delivery

steps of this research were in line with the guidelines of the Vision

local approaches such as intraarterial,

intravitreal,

of greater concentrations of drugs into the eye.3,4 As a result, direct

and Ophthalmology Research Association Statement on the Use of

intravitreal injection is the optimal method for obtaining adequate

Animals in Ophthalmic and Vision Research (ARVO).

concentrations in the vitreous cavity.3,4

Previous studies demonstrated overall similarities between

The rationale for local retinoblastoma therapy is to deliver higher

rabbit and human eyes. At the anatomical and histological levels,

concentrations of chemotherapy adjacent to tumor cells, minimizing

different parts of the human and rabbit eyes especially the vitre-

systemic adverse reactions.18

ous matrices, are sufficiently similar to make the rabbit a promis-

Melphalan is currently the most common medication used for
19

intravitreal chemotherapy in retinoblastoma.

ing animal model for the study.39 Therefore, eighteen New Zealand

The adverse eye

rabbits, weighing between 2 and 3 kg, were used to evaluate the

effects of Melphalan, such as toxicity to the posterior and anterior

safety of repeated intravitreal injections of Carboplatin and Digoxin.

segments, 20–23 prompted researchers to look for other possible

Baseline ocular examination with hand-held slit lamp and indirect

chemotherapeutic agents for intravitreal injection.

24,25

Moreover,

ophthalmoscopy and ERG using the electrophysiological test sys-

a second chemotherapeutic agent is usually required to reduce

tem (Metrovision, France) were done for all animals. Rabbits with

the number of injections, and serve as an alternative in cases with

documented baseline anterior or posterior segment abnormalities in

intravitreal melphalan resistance.19 Thiotepa, 26 Methotrexate, 27

the eye were excluded. They are repeated at 1st day, 1st week, and

10,19

Topotecan,

Etoposide,

2

18,28

Carboplatin,

and Digoxin

29

were

1st month after the last injection. The following the interventions

evaluated as other intravitreal chemotherapeutics in retinoblastoma.

conjunctival injection, corneal status, lens condition, any pathologic

Among these alternatives the in vivo safety studies on repeated in-

findings in the retina, and anterior and posterior segments reaction

travitreal injection of Digoxin and Carboplatin, as available agents

were evaluated.

especially in developing countries, is limited.
Carboplatin is an essential part of the most active chemotherapy regimens for retinoblastoma care (Vincristine, Etoposide,

2.1 | Treatment groups

Carboplatin-  VEC).17 Lower toxicity and higher efficacy of
Carboplatin, make it a good possible option for intravitreal chemo-

The rabbits were randomly divided to receive an intravitreal injec-

therapy. 2 There are several studies that show the effectiveness of

tion of 1 µg Carboplatin (Thymo organ pharmazie GmbH) diluted

intravitreal injection of Carboplatin,12,18,30 however, there are lim-

with 0.1 cc Saline (N = 7), or 10 µg Digoxin (Sterop) diluted with

ited data regarding the ocular safety and possible toxicity after re-

0.1 cc Saline (N = 6), or 0.1 cc Saline alone (N = 5). In each group, one

peated intravitreal injections. 28,31,32

eye randomly treated with intravitreal injection and the contralateral

Digoxin is a cardiac glycoside traditionally used in the treatment

eye was considered as the non-dosed control (without any interven-

of heart failure and arrhythmia.33 Anti-proliferative and cytotoxic

tion). All groups underwent three consecutive injections of the drugs

effects of Digoxin were shown in several experimental studies.33–36

with 1-week intervals.

In addition, the anti-tumor activity of Digoxin on retinoblastoma

For the Carboplatin group, the dose chosen dose was close to the

cells was demonstrated in vitro in previous investigations.37 One

maximum tolerated dose to achieve the most effective concentra-

case of retinoblastoma treated with oral and intraarterial Digoxin

tion (1 µg), based on previous investigations. 28,30–32 For the Digoxin

was reported in a clinical study and there was a modest intraarterial

group, the dosage was chosen based on the amount of Digoxin that

|
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could result in pharmacologically active amounts in the vitreous of

were divided into two parts by an anterior-posterior incision. Then

a rabbit (1.5 ml) for at least 4 h after injection, as well as a low sys-

the histological processing was applied and 4-µm-thick cut specimens

temic exposure as a proxy of cardiac toxicity for its direct impact in

were stained with hematoxylin and eosin and observed under a light

the translation to clinics, which was the end goal of these studies.40

microscope (Olympus BX41). All specimens were studied by the same

As a result, the dose was determined by the biological activity

pathologist (FA), and all ocular layers were evaluated for the presence

threshold, or IC50, and we chose the value obtained by Antczak

of any kind of inflammation, hemorrhage, congestion, necrosis, de-

et al. (10 µg).37

generation, and atrophic changes. The retina was assessed carefully
for the thickness of different layers, presence or absence of retinal
pigment epithelium (RPE), photoreceptors, and ganglion cells.

2.2 | Intravitreal injection technique
The rabbits were anesthetized with a mixture of 25 mg/kg Ketamine

2.5 | Statistical analysis

10% (Alfasan) and 2 mg/kg Xylazine 2% (Alfasan). The injection was
performed under a sterile condition after anterior chamber paracen-

All data were analyzed using SPSS software (Version 22.0. Armonk:

tesis (0.05 ml) using a 29-gauge needle. All the injections were per-

IBM Corp.). Wilcoxon test was used for evaluating the ERG value

formed through 1.5 mm posterior to the limbus into the midvitreous.

changes within groups. It was also used for the difference of the

The needle was held in place for 15 s after injection to prevent reflux

injected eye versus contralateral (control) eye in different follow-ups

from the entrance site.

in each group. We used the Mann–Whitney test to compare ERG
values between the groups. A p-value less than .05 was considered
statistically significant.

2.3 | Electroretinography
The full-field ERG measures the retina's mass electrical response

2.6 | Nomenclature of targets and ligands

to photic stimulation. It is a test that evaluates the function of the
retina in human patients and laboratory animals.41

Key protein targets and ligands in this article are hyperlinked

The a-wave is the first large negative component, followed by

to corresponding entries in http://www.guidetopharmacology.

the b-wave which is a positive wave and usually larger in amplitude.

org, the common portal for data from the IUPHAR/BPS Guide to

The a-wave, also known as the “late receptor potential,” reflects the

PHARMACOLOGY (Harding et al., 2018),43 and are permanently

overall physiological health of the photoreceptors in the outer ret-

archived in the Concise Guide to PHARMACOLOGY 2019/20

ina. In contrast, the b-wave reflects the health of the inner layers of

(Alexander et al., 2019).44

retina, including the Muller cells and bipolar cells.

42

Flash electroretinography (ERG-Metrovision) was recorded at
baseline, 1 day, 1 week, and 1 month after the last injection to evaluate the possible toxicity on the retina's function. Before the test,
the rabbits were dark-adapted for 45 min and prepared under dim

3
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3.1 | Clinical evaluation

red light. Animals were anesthetized before recording ERG, with an
intramuscular injection of the ketamine and xylazine (25/2 mg/kg).

Twenty rabbits were randomly divided into three groups of Digoxin

Pupils were dilated using tropicamide (1%) and tetracaine hydrochlo-

(7 rabbits), Carboplatin (7 rabbits), and Salin (6 rabbits); however, one

ride (0.5%). The retinal electrical response was recorded by Goldring

rabbit from the Digoxin group and one from the Saline group died on

recording electrode (4 mm, Roland Consult). After placement of the

the first day with unknown reasons. The other rabbits completed the

reference electrode (stainless steel needle electrode) at the base

experimental period. No obvious changes in food or water intake as

of the ear subcutaneously and the ground electrode on the tail,

a sign of the general toxicity were observed. In the ocular examina-

the main recording electrode was inserted on the corneal surface.

tions of the rabbits at baseline, 1st day, 1st week, and 1st month

The scotopic ERG was recorded by applying eight-light stimuli with

after the last injection, we did not find any noticeable findings such

125 cdsm−2. The average of the responses from four separate light

as corneal opacity, cataract, hemorrhage, or inflammation in the an-

stimuli was documented.

terior chamber and vitreous cavity. There was no phthisis bulbi in
any of our groups.

2.4 | Histological assessments

3.2 | ERG findings

All animals were euthanized with overdosing of thiopental sodiumone
month after the last injection and enucleated. Then the eyes were

In the Digoxin group, mean a-wave amplitude in injected eyes at the

stored in Davidson's fixative solution. After the fixation, the specimens

1st day (−19.8 ± 16.6 µv, p-value: .02), 1st week (−23.7 ± 23.8 µv,

4 of 9
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p-value: .02) and 1st month (−18.4 ± 17.8 µv, p-value: .02) after the
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reduced. However, the retinal pigment epithelium (RPE) layer re-

last injection were significantly lower than baseline (−33.8 ± 6.7 µv)

mained unchanged in most of the specimens (Figure 3C). Additionally,

(Figures 1 and 2, Table 1 and Table S1).

in two specimens, chronic vitritis with lymphoplasmacytic infiltration was found in the posterior pole, especially around the optic disc

3.3 | Histological findings

(optic neuritis) (Figure 4A). Furthermore, severe choroidal congestion with or without ciliary body congestion was seen in all of the
specimens of the Digoxin injected eyes (Figure 4B).

Based on histopathological findings, there were no distinguishable

In the Carboplatin group, there was no sign of inflammation in

histological changes in both the Saline group and the contralateral

the anterior and posterior segments of the eyes. All specimens had

control eyes of each group (Figure 3A and B).

normal retinal thickness, ganglion cells, photoreceptor morphology,

In the Digoxin group, substantial neural retinal atrophy was seen

pigmented epithelial cells, and nuclear layers. No evidence of optic

in five of six specimens (83.3%). The thickness of the ellipsoid zone,

nerve edema, neuritis, or atrophy, as well as retinal hemorrhages,

ganglion cells layer, inner, and outer nuclear layer was considerably

was identified (Figure 3D).

F I G U R E 1 Scotopic
electroretinographs (ERG) of injected and
contralateral control eyes of three rabbits
in Saline, Digoxin and Carboplatin groups
at baseline, 1st day, 1st week, and 1st
month after the last injection

F I G U R E 2 The linear graphs of ERG
values demonstrating change in their
means at baseline, 1st day, 1st week, and
1st month after the last injection in each
group of injected and contralateral control
eyes

−33.8 ± 6.7

−34.4 ± 6.5

Digoxin

Carboplatin

−19.8 ± 16.6

−33.3 ± 5.1

Digoxin

Carboplatin

−23.7 ± 23.8

−39.2 ± 9

Digoxin

Carboplatin

41.5 ± 41.4

−18.4 ± 17.8

−33.4 ± 8.3

Digoxin

Carboplatin

13.9 ± 1

14.4 ± 7.1

13.9 ± 1.2

14 ± 0.7

13 ± 7

13.9 ± 0.4

14.1 ± 0.6

16.4 ± 6.2

14.3 ± 0.7

13.6 ± 0.9

14.4 ± 0.7

13.7 ± 1.5

35.2 ± 1.7

29.4 ± 13.2

33.6 ± 2.9

34.3 ± 3.6

27.8 ± 16

35.5 ± 1.6

32.9 ± 3.4

32.3 ± 10.5

34.5 ± 1.8

36.2 ± 1.4

34.9 ± 2.8

34.7 ± 2.2

−33.9 ± 6.9

−34.2 ± 3.3

−36.1 ± 7.1

−33.5 ± 7.2

−46.7 ± 7.03

−46.5 ± 13.2

−36.6 ± 2.8

−34.8 ± 10.9

−35.1 ± 4.9

−35.9 ± 1.2

−34.4 ± 9.9

−38.06 ± 6.7

80.2 ± 17.7

75.2 ± 20.7

77.9 ± 21.7

57.1 ± 10.3

84.3 ± 19.5

91.2 ± 22.3

88.2 ± 9.5

80 ± 19.4

81.6 ± 19.03

72.8 ± 14.5

82.1 ± 30.1

77.7 ± 29.8

b (µv)
(mean ± SD)

14.08 ± 1.4

13.8 ± 1.1

13.8 ± 1.2

14.2 ± 0.57

15.1 ± 1.2

13.9 ± 0.21

13.8 ± 0.6

15.08 ± 0.89

13.9 ± 0.8

14.08 ± 0.75

14.7 ± 0.48

13.9 ± 1.8

al (ms)
(mean ± SD)

36.2 ± 1.1

35.5 ± 1.8

34.08 ± 2.66

34.7 ± 3.5

35.9 ± 3.2

35.2 ± 2.01

34.3 ± 2.4

37.6 ± 0.4

34.4 ± 1.3

36.1 ± 1.5

36.04 ± 1.9

35.6 ± 1.5

bl (ms)
(mean ± SD)

0.65

0.004*

0.25

0.4

0.004*

0.17

0.22

0.004*

0.91

0.52

0.87

0.75

a

*Statistical significant p-value less than .05.

bl¶: b-wave latency (ms).

al§: a-wave latency (ms).

a†: a-wave amplitude (µv).
b‡: b-wave amplitude (µv).

0.4

0.004*

0.91

0.01*

0.004*

0.17

0.18

0.004*

0.6

0.74

0.42

0.91

b

0.74

0.47

0.83

0.21

1.00

0.27

0.4

0.26

0.2

0.36

0.2

0.83

al

0.6

0.1

0.82

0.4

0.05

1.00

0.7

0.004*

0.7

0.56

0.1

0.2

bl

p-value between injected & control
eye

p-value for comparison of ERG values between injected eye and contralateral control eye at different intervals after the last injection was demonstrated in each group.

74.2 ± 20.5

77.8 ± 20.7

70.1 ± 16.5

42.6 ± 43.8

81 ± 20.9

76 ± 18.2

44.9 ± 38.5

83.4 ± 26.5

67.1 ± 12.1

77.7 ± 24.2

73.7 ± 23.6

−34.7 ± 6.1

Saline

1st month

−40.5 ± 11.9

Saline

1st week

−33.5 ± 8.5

Saline

1st day

−37.6 ± 6.1

Saline

Base

bl¶ (ms)
(mean ± SD)
a (µv)
(mean ± SD)

al§ (ms)
(mean ± SD)

a† (µv)
(mean ± SD)

b‡ (µv)
(mean ± SD)

Control eye

Injected eye

TA B L E 1 Detailed scotopic electroretinographic (ERG) results including mean±standard deviation (SD) of a-wave amplitudes (µv), b-wave amplitudes (µv), a-wave latency (ms) and b-wave
latency (ms) at baseline, 1st day, 1st week, and 1st month after the last injection in each group in comparison with their contralateral control eyes
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F I G U R E 3 (A) Retinal histological
specimen of a control eye, stained
with hematoxylin and eosin. (B) Retinal
histological specimen of the Saline-
injected eye. (C) Retinal histological
specimen of the Digoxin-injected eye
(retinal atrophy is an apparent finding).
(D) Retinal histological specimen of the
Carboplatin-injected eye. Abbreviations:
GCL, Ganglion Cells Layer; INL, Inner
Nuclear Layer; ONL, Outer Nuclear Layer,
photoreceptors: photoreceptors layer

F I G U R E 4 (A) Optic disc histological
specimen of the Digoxin-injected eye.
(B) Obvious choroidal congestion in the
Digoxin-injected eye

4
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DISCUSSION

histological findings, which revealed neural retinal atrophy as well
as severe choroidal congestion. Furthermore, chronic inflammation

In this experimental study, we investigated the ocular safety of

around the optic disc was found in two eyes. The reduction in both

repeated intravitreal injections of 1 µg/0.1 cc Carboplatin and

amplitudes may be the result of the injected volume or a toxic effect

10 µg/0.1 cc Digoxin as an available potential candidates for intravit-

of the agent; however, the ERGs remained unchanged in the Saline

real chemotherapy in the treatment of retinoblastoma. Our results

group, despite receiving three consecutive injections with the same

showed that repeated intravitreal injections of 10 µg Digoxin could

volume. Therefore, the elevation of IOP from increased intraocular

have noticeable intraocular toxicity based on ERG and histological

volume after injection was not the cause of these findings.

investigations in albino rabbit eyes. Contradictory, 1 µg Carboplatin
injected eyes had minimal ERG and pathologic changes.

To the best of our knowledge, there was only one study in the
literature evaluating the ocular safety of intravitreal injection of

ERG values, including mean a-wave amplitude and mean b-wave

Digoxin in rabbit eyes. In consistent with our findings, Winter et al. 29

amplitude decreased significantly after repeated intravitreal injec-

revealed that retinal toxicity appeared after three consecutive in-

tions of 10 µg Digoxin at 1st day, 1st week, and 1st month after

jections of the 1 µg Digoxin based on ERG changes and histologic

the last injection in comparison with the Carboplatin and the Saline

findings. They encountered severe retinal damage and complete

groups. ERG results in the Digoxin group were consistent with the

loss of a- and b-wave in ERG 1 week after an intravitreal injection

|
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of 10 µg Digoxin. In contrast to their experience, we did not see

administration of Carboplatin 4 μg plus Topotecan 0.1 μg also

such profound damage with repeated intravitreal injection of 10 µg

showed similar efficacy (about 80%). However, reduced retinal

Digoxin. In the pharmacokinetic evaluation of their study on 17 rab-

toxicity (approximatively 25% of eyes with a decrease in retinal

bits with a single intravitreal injection of 10 µg Digoxin, Digoxin was

thickness) was induced at weekly 1.5 μg Carboplatin as well as

not detected in vitreous and retina of contralateral non-injected

biweekly combination therapy, while an important percentage of

eyes. Interestingly, we found some ERG changes in the non-injected

toxicity (62.5% of the eyes with a decrease in retinal thickness)

control eyes in the Digoxin and Carboplatin groups in comparison

was observed with 4 μg of Carboplatin weekly injection based

with the contralateral non-injected eyes of the Saline group. The re-

on optical coherence tomography findings. They proposed that

peated intravitreal injection of the agents used in our study might

the cumulative injected dose (addition of all the repeated doses),

be an explanation for these ERG changes in non-injected eyes. We

as well as the time interval between two injections (frequency),

assume that repeated intravitreal injection of these chemo-agents

impact the efficacy/toxicity balance.

may cause damage to the ocular-blood barrier that leads to the sys-

Besides, they found ocular complications related to the intravit-

temic absorption of these drugs.45 The clinical significance of these

real injection technique, including media opacity and retinal detach-

changes should be assessed in future studies.

ment, which were not seen in our study.

In contradiction to Digoxin, repeated intravitreal injections of

The main drawback of animal studies is the translation to clinics

1 µg Carboplatin showed promising results according to functional

for retinoblastoma treatment. The direct extrapolation of the doses

and morphologic findings. There were more studies on the ocular

used in the animal eye to the children's eye in order to treat reti-

safety of intravitreal Carboplatin in literature with different doses.

noblastoma is debatable. Preclinical animal trials are necessary to

Susskind et al. have shown that Carboplatin is less toxic to RPE cells

examine the outcome of various chemotherapy agents on the eyes,

in comparison with Melphalan and Topotecan.4 Francis et al. revealed

but more things we need to learn about the application to clinics.

that Carboplatin led to minimal changes in electroretinogram after in-

All these rabbits had healthy eyes and we do not know whether the

46

traarterial chemotherapy compared to Melphalan and Topotecan.

According to our results, Zlioba et al. 31 evaluated intravitreal

safety profile observed in this study will be the same in the eyes with
retinoblastoma or not. We also did not assess the efficacy of the

Carboplatin toxicity in rabbit eyes and showed no ocular toxicity

dose–response of drugs on tumor cells, and further investigation is

based on histological and electroretinographic observations for

needed to assess the efficacy as well as the safety of these drugs in

doses up to 3 μg. Pochop et al. 32 investigated the retinal toxicity

transgenic retinoblastoma models.

of repeated intravitreal injection (4 times with 2 weeks intervals)

Certain drawbacks of our study were the low sample size and

of 8 µg Carboplatin. They demonstrated reduced dark-adapted b-

no assessment of the intravitreal concentration of drugs. Moreover,

wave amplitudes and light-adapted b-wave and a-wave amplitudes

we did not evaluate the dose–response for each drug in this survey.

in electroretinography studies. However, they didn't find remark-

This research examined the functional and anatomical changes up to

able histopathologic retinal change compatible with drug toxicity.

1 month after the last injection, and did not rule out the possibility

In contrast to our study, they also found some significant ERG

of long-term toxicity or rehabilitation following such repeated injec-

changes in the control eyes that were injected with Saline. Hence,

tions. In addition, the effect of each injection on ERG parameters

they attributed these changes to transient retina ischemia caused

was not assessed separately.

by rapid elevation of intraocular pressure. They suggested the 8 µg

As ERG is primarily a functional test of the status of the photore-

of Carboplatin as the highest possible safe dose for intravitreal

ceptors and bipolar cells, the normal ERG results do not exclude pos-

injection.

sible damage at the level of the retinal ganglion cells or their axons,

Retinal toxicity, along with widespread outer retina disruption,

although this was not seen in histological evaluations. Conversely,

has been observed for intravitreal injection of Carboplatin at the

safety based on histological findings by light microscopy cannot rule

dose of 10 µg or higher.18 Carboplatin has shown impressive out-

out possible changes at the submicroscopic level. Therefore, it is

comes in terms of the efficacy/toxicity balance in a transgenic model

better to design a study to perform immunocytochemical analysis

by Harbour et al. They used different doses of Carboplatin, 1.4 and

on the histopathologic sections to evaluate the possible damage to

4 μg, with different intervals for intravitreal injections and revealed

retinal microstructures.

that low doses every week seem to be equally efficient as high doses
every 2 weeks with a lower chance for retinal toxicity. Serial doses
of intravitreal Carboplatin can effectively inhibit tumor growth in a
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dose-dependent manner.
Recently Lemaître et al. 28 evaluated the effectiveness and

Intravitreal 10 µg Digoxin might have more local ocular toxicity

safety of intravitreal injection of Melphalan, Topotecan, and

in comparison with intravitreal Carboplatin in albino rabbit eyes

Carboplatin, alone or in combination in the animal model of

based on ERG and histopathological findings. Future studies

LHBetaTag retinoblastoma mice. They found that weekly intra-

should evaluate the possible effects of intravitreal chemotherapy,

vitreal Carboplatin, either 1.5 or 4 μg could reduce tumor bur-

specially on non-injected fellow eyes of the retinoblastoma rabbit

den significantly (80%). The sequential (injection every 2 weeks)

models.
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